Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigational new drug (IND) and/or clinical trial application (CTA) for PM577, its Prime Editor for the treatment of H1069Q-driven Wilson’s Disease, in the first half of 2026, with initial clinical data expected in 2027.

Read more at globenewswire.com